Search Results for: "Other News to Note"
-
Other News To Note
The two companies also said they received a positive opinion from the European Committee for Medicinal Products for Human Use for Jentadueto, which combines DPP-4 inhibitor linagliptin (the active ingredient in Trajenta) and metformin in a single tabletBioWorld International | Wednesday, May 30, 2012 -
Pharma: Other News To Note
Almirall SA, of Barcelona, Spain, said the European Committee for Medicinal Products for Human Use issued a positive opinion for Eklira Genuair (aclidinium) as a maintenance bronchodilator treatment to relieve symptoms in adults with chronic obstructive pulmonary disease...Eisai Inc., of Woodcliff Lake, N.J., said the European Committee for Medicinal Products for Human Use issued a positive opinion for Fycompa (perampanel) as an adjunctive treatment of partial-onset seizures, with or withoutBioWorld Today | Wednesday, May 30, 2012 -
Pharma: Other News To Note
Boehringer Ingelheim GmbH, of Ingelheim, Germany, and Eli Lilly and Co., of Indianapolis, said they received a positive opinion from the European Committee for Medicinal Products for Human Use for Jentadueto, which combines DPP-4 inhibitor linagliptin (the active ingredient in Trajenta) and metformin in a single tabletBioWorld Today | Tuesday, May 29, 2012 -
Other News To Note
Vertex Pharmaceuticals Inc., of Cambridge, Mass., received a positive opinion from the European Committee for Medicinal Products for Human Use for approval of Kalydeco (ivacaftor) for cystic fibrosis in those age 6 and older with at least one copy of the G551D mutationBioWorld Today | Tuesday, May 29, 2012 -
Other News To Note
In other news, Gentium said it received the Day 180 list of outstanding issues from the European Committee for Medicinal Products for Human Use in connection with the marketing authorization application for Defibrotide to treat and prevent hepatic veno-occlusive disease in adults and children undergoing hematopoietic stem cell transplantation therapyBioWorld International | Wednesday, May 9, 2012 -
Other News To Note
Gentium SpA, of Villa Guardia, Italy, said it received the Day 180 list of outstanding issues from the European Committee for Medicinal Products for Human Use in connection with the marketing authorization application for Defibrotide to treat and prevent hepatic veno-occlusive disease in adults and children undergoing hematopoietic stem cell transplantation therapyBioWorld Today | Monday, May 7, 2012 -
Other News To Note
Novartis AG, of Basel, Switzerland, received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for Jakavi (ruxolitinib), its myelofibrosis treatmentBioWorld International | Wednesday, April 25, 2012 -
Pharma: Other News To Note
Novartis AG, of Basel, Switzerland, received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for Jakavi (ruxolitinib), its myelofibrosis treatmentBioWorld Today | Monday, April 23, 2012 -
Other News To Note
Ltd., of Osaka, Japan, said the European Committee for Medicinal Products for Human Use issued a positive opinion for ferumoxytol, an intravenous iron therapy, with a proposed indication for the treatment of iron deficiency anemia in adults with chronic kidney disease...SkyePharma plc, of London, reported Friday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending granting of a marketing authorizationBioWorld Today | Monday, April 23, 2012 -
Other News To Note
The decision follows a positive recommendation from the Committee for Medicinal Products for Human Use late last year...Shire plc, of Dublin, Ireland, said the European Committee for Medicinal Products for Human Use approved the production of Vpriv (velaglucerase alfa) in the firm's new manufacturing facility in Lexington, MassBioWorld International | Wednesday, February 29, 2012 -
Other News To Note
The decision follows a positive recommendation from the Committee for Medicinal Products for Human Use late last yearBioWorld Today | Tuesday, February 28, 2012 -
Pharma: Other News To Note
Shire plc, of Dublin, Ireland, said the European Committee for Medicinal Products for Human Use approved the production of Vpriv (velaglucerase alfa) in the firm's new manufacturing facility in Lexington, MassBioWorld Today | Thursday, February 23, 2012 -
Other News To Note
Gentium SpA, of Villa Guardia, Italy, responded to the day 120 list of questions from the European Committee for Medicinal Products for Human Use regarding defibrotide in the treatment and prevention of hepatic veno-occlusive disease in patients undergoing hematopoietic stem cell transplantationBioWorld Today | Wednesday, February 22, 2012 -
Pharma: Other News To Note
Abbott, of Abbott Park, Ill., said the European Committee for Medicinal Products for Human Use issued a positive opinion for Humira (adalimumab) in adults with moderate to severely active ulcerative colitis who have not responded to, cannot tolerate or have medical contraindications to conventional therapiesBioWorld Today | Tuesday, February 21, 2012 -
Other News To Note
Amylin Pharmaceuticals Inc., of San Diego, and Eli Lilly and Co., of Indianapolis, said the European Committee for Medicinal Products for Human Use issued a positive opinion for expanded use of Byetta (exenatide twice-daily) for treatment of Type II diabetes...Cell Therapeutics Inc., of Seattle, said the European Committee for Medicinal Products for Human Use (CHMP) gave a positive opinion on conditional approval of Pixuvri (pixantrone dimaleate) for non-Hodgkin's B-cell lymphomasBioWorld Today | Tuesday, February 21, 2012 -
Other News To Note
PregLem, a subsidiary of Gedeon Richter, recently received a positive opinion from the European Committee for Medicinal Products for Human Use for Esmya, a selective progesterone receptor modulatorBioWorld International | Wednesday, February 8, 2012 -
Other News To Note
Furiex Pharmaceuticals Inc., of Morrisville, N.C., said the European Commission (EC) endorsed a positive opinion adopted by the Committee for Human Medicinal Products Oct. 18, 2011, regarding Prilogy (dapoxetine) 30-mg and 60-mg doses for use in premature ejaculation in men between the ages of 18 and 64BioWorld Today | Thursday, February 2, 2012 -
Other News To Note
Allos Therapeutics Inc., of Westminster, Colo., submitted its request for a reexamination of the European Committee for Medicinal Products for Human Use (CHMP)'s negative opinion regarding approval of Folotyn (pralatrexate injection) for peripheral T-cell lymphoma...Amsterdam Molecular Therapeutics NV, of Amsterdam, the Netherlands, reported that rather than approve the Committee for Human Medicinal Products' recommendation to deny marketing authorization for Glybera (alipogene tiparvovec), theBioWorld Today | Tuesday, January 31, 2012 -
Other News To Note
Allos Therapeutics Inc., of Westminster, Colo., received a negative opinion from the European Committee for Medicinal Products for Human Use (CHMP) regarding approval of Folotyn (pralatrexate injection) for peripheral T-cell lymphomaBioWorld Today | Monday, January 23, 2012 -
Other News To Note
Gentium SpA, of Villa Guardia, Italy, said it received the list of questions from the European Committee for Medicinal Products for Human Use in response to its marketing application for defibrotide to treat and prevent hepatic veno-occlusive disease in adults and children undergoing hematopoietic stem cell transplantation therapyBioWorld International | Wednesday, January 4, 2012
Category
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.